WUHU, China, June 6, 2025 /PRNewswire/ -- In the recently concluded 2025 Taklamakan Rally (TAR), the JETOUR G700 achieved remarkable results. Driven by Li Chengpeng and Zhang Jianfeng, the JETOUR G700 participated in the race before its official launch. It won multiple group stage championships, and the entire team successfully finished the race, conquering 4,500 km of China's most brutal terrain over 13 grueling days. This victory not only shattered doubts about the off-road capabilities of new energy vehicles but also showcased JETOUR's innovation on the global stage.
Unstoppable Performance: G700 Dominates the "New Hell" of Off-Roading
The 2025 TAR Rally raised the stakes with extended routes totaling 2,350 km of special stages, weaving through deserts, canyons, and riverbeds. The G700 dominated iconic sections like Yue Liang Po and the perilous N39 "Death Stage," where scorching heat and relentless sandstorms tested its limits. Competing against elite rivals across 12 treacherous stages, the G700 stood out.
GAIA Architecture: The Unstoppable Force Behind Victory
The fuel-powered vehicles have long dominated premium off-roading due to new energy limitations in extreme terrain, while JETOUR's GAIA architecture breaks the mold. Its dual-power Super Hybrid and Amphibious Range-Extender systems deliver instant torque, sustained power, and extended range—finally bringing electrified performance to the most demanding environments.
Key to its success was the Super Hybrid system, featuring a 2.0TD engine with 45.5% thermal efficiency and an 800V 4C battery capable of 490kW discharge power. The G700 tackled extreme conditions with unwavering reliability, thanks to its 1,300 MPa armored battery casing and real-time temperature monitoring.
Relentless Stability, Uncompromising Reliability: The G700's Winning Formula
The G700's unibody frame, triple differential locks, and adjustable suspension ensured stability across diverse terrains. In the SS3 Kepin Stage, its cloud-platform chassis excelled in rocky canyons, while intelligent terrain management aced the shifting sands of SS2 Alar. Driver Li Chengpeng praised its comfort: "Unlike traditional off-roaders, the G700 lets you enjoy the ride even on brutal corrugated roads."
A New Era Begins: The Future of Electrified Off-Roading
With cutting-edge hybrid technology and battle-tested resilience, the G700 embodies the future of adventure, proving that innovation and endurance can conquer any terrain. The model is expected to make its global debut in the fourth quarter of this year. With performance surpassing expectations, the G700 is poised to go "Beyond the Horizon".
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
JETOUR G700's Historic Debut at the 2025 Taklimakan Rally
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
